{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-053351","form_type":"8-K","ticker":"VIR","cik":"0001706431","company_name":"Vir Biotechnology, Inc.","filed_at":"2026-08-05T20:09:55+00:00","discovered_at":"2026-08-05T20:11:00.233951+00:00","generated_at":"2026-08-05T20:11:46.898860+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vir Biotechnology Q2 net income $80.1M on Astellas deal; cash $1.01B","bullets":["Net income of $80.1M ($0.48 diluted EPS) vs net loss of $111.0M in Q2 2025.","Revenue $238.9M, primarily from $240M Astellas upfront payment; cash $1.01B.","Phase 2 SOLSTICE: 88% of CHD patients achieved undetectable HDV RNA at Week 96.","Phase 3 ECLIPSE 1 topline data expected Q4 2026; ECLIPSE 2 fully enrolled.","Appointed Timothy Coughlin to Board and as Audit Committee Chair."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-053351","json":"https://secwatch.observer/filing/0001628280-26-053351.json","markdown":"https://secwatch.observer/filing/0001628280-26-053351.md","text":"https://secwatch.observer/filing/0001628280-26-053351.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026053351/0001628280-26-053351-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026053351/vir-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:11:46.898860+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}